Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting

Clinical Therapeutics

Volumn 31, Issue 5, 2009, Pages 1116-1123

  McAdam Marx, Carrie ^a   Ye, Xiangyang ^a   Sung, Jennifer C ^b   Brixner, Diana I ^a   Kahler, Kristijan H ^b  

^a UNIVERSITY OF UTAH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ambulatory care; blood pressure; community practice; resistant hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; AMBULATORY CARE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CLINICAL FEATURE; COMMUNITY CARE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; OBESITY; OBSERVATIONAL STUDY; PILOT STUDY; PREVALENCE; RETROSPECTIVE STUDY; UNITED STATES;

AGED; AMBULATORY CARE; AMBULATORY CARE FACILITIES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY MASS INDEX; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIURETICS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; PILOT PROJECTS; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 66949115332     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.05.007     Document Type: Article

References (18)

1. Rosamond W., Flegal K., Furie K., et al., the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2008 Update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 (2008) e25-e146
2. Hajjar I., and Kotchen T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 290 (2003) 199-206
3. Epstein M. Resistant hypertension: Prevalence and evolving concepts. J Clin Hypertens (Greenwich) 9 Suppl 1 (2007) 2-6
4. Ho P.M., Magid D.J., Shetterly S.M., et al. Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch Intern Med. 168 (2008) 271-276
5. Park J., and Campese V. Clinical characteristics of resistant hypertension: The importance of compliance and the role of diagnostic evaluation in delineating pathogenesis. J Clin Hypertens (Greenwich) 9 Suppl 1 (2007) 7-12
6. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51 (2008) 1403-1419
7. Black H.R., Elliott W.J., Grandits G., et al., the CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 289 (2003) 2073-2082
8. Cushman W.C., Ford C.E., Cutler J.A., et al., the ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 4 (2002) 393-404
9. Oderda G., Lieberman M., Asche C., and Brixner D. Use of electronic medical record (EMR) data in outcomes research. Value Health 10 (2007) A450-A451
10. Basic Counts and Population Estimates for 2005. http://www.census.gov/ Accessed June 1, 2007
11. 2007 ICD-9-CM Volume 1 Diagnosis Codes. http://www.icd9data.com/2007/Volume1/default.htm Accessed April 29, 2009
12. US Dept of Health and Human Services. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. http://www.nhlbi.nih.gov/guidelines/ hypertension/express.pdf Accessed February 12, 2007
13. Dean BB, Lam J, Natoli JL, et al. Use of electronic medical records for health outcomes research: A literature review [published online ahead of print March 11, 2009]. Med Care Res Rev.
14. Black H.R., Elliott W.J., Neaton J.D., et al. Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial. Control Clin Trials 19 (1998) 370-390
15. Davis B.R., Cutler J.A., Gordon D.J., et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 9 (1996) 342-360
16. Chobanian A.V., Bakris G.L., Black H.R., et al., the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report [published correction appears in JAMA. 2003; 290:197]. JAMA 289 (2003) 2560-2572
17. Vasan R.S., Beiser A., Seshadri S., et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 287 (2002) 1003-1010
18. Mensah G.A. Public health and the control of high blood pressure at the state level: Asleep at the switch or running low on fuel. Circulation 117 (2008) 860-862